2021
DOI: 10.1002/mrm.28842
|View full text |Cite
|
Sign up to set email alerts
|

The LEGATOS technique: A new tissue‐validated dynamic contrast‐enhanced MRI method for whole‐brain, high‐spatial resolution parametric mapping

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
34
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5

Relationship

3
2

Authors

Journals

citations
Cited by 7 publications
(34 citation statements)
references
References 43 publications
0
34
0
Order By: Relevance
“…The 25 patients with GBM and 29 patients with sporadic VS were all imaged once on a 1.5 T scanner (Philips Achieva, Best, Netherlands). Thirteen of the included patients with GBM and twenty-two of the included patients with sporadic VS had been recruited and scanned as part of previous published studies at our institution 1 , 2 , 6 . The twelve patients with NF2-related VS had similarly been recruited as part of an earlier published study investigating bevacizumab (Avastin ©) related changes in DCE-MRI derived kinetic parameters in VS and these patients had been imaged twice at 1.5 T: pre-treatment (day 0) and 3 months (day 90) following bevacizumab (Avastin ©) treatment.…”
Section: Methodsmentioning
confidence: 99%
See 4 more Smart Citations
“…The 25 patients with GBM and 29 patients with sporadic VS were all imaged once on a 1.5 T scanner (Philips Achieva, Best, Netherlands). Thirteen of the included patients with GBM and twenty-two of the included patients with sporadic VS had been recruited and scanned as part of previous published studies at our institution 1 , 2 , 6 . The twelve patients with NF2-related VS had similarly been recruited as part of an earlier published study investigating bevacizumab (Avastin ©) related changes in DCE-MRI derived kinetic parameters in VS and these patients had been imaged twice at 1.5 T: pre-treatment (day 0) and 3 months (day 90) following bevacizumab (Avastin ©) treatment.…”
Section: Methodsmentioning
confidence: 99%
“…DCE-MRI data was acquired using a previously described DTR, dual injection technique 6 , 16 , 28 . Single dose macrocyclic GBCA (gadoterate meglumine; Dotarem, Guerbet S.A.) was used at a dose of 0.2 ml/kg.…”
Section: Methodsmentioning
confidence: 99%
See 3 more Smart Citations